AMERICAN SALARS ADOPTS ESG POLICY AHEAD OF DEVELOPMENT OF ITS MULTIPLE LITHIUM BRINE DEPOSITS Read more
Io Therapeutics, Inc., presented data from studies of IRX4204, the company’s phase II clinical development stage, highly selective third generation RXR nuclear receptor agonist compound, supporting its potential use for prevention and treatment of normal aging-related neurodegeneration, Parkinson’s disease, and Alzheimer’s disease Read more
Calibre Receives Environmental Approval for Development and Operation of the Volcan Gold Deposit located in the Libertad Mine Complex Read more